B2M and cancer: Targeting NLRC5 promoter demethylation through TRED-I system can upregulate MHC-I, B2M, TAP1 and genes encoding immune proteasome components (LMP2/PSMB9/β1i, LMP7/PSMB8/β5i), thereby enhancing CD8+T cell-mediated anti-cancer immunity.